Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Neurology

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.25165PMID 29394504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke.

  2019cited by this paper
• Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants

  2017cited by this paper
• Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

  2017cited by this paper
• Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents.

  2017cited by this paper
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

  2016cited by this paper
• When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

  2016cited by this paper
• Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke

  2016cited by this paper
• Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke

  2016cited by this paper
• Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.

  2016cited by this paper
• Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

  2016cited by this paper
• Recanalization Therapies in Acute Ischemic Stroke Patients: Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Outcome

  2015cited by this paper
• Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

  2015cited by this paper
• Point-of-Care Testing of Coagulation in Patients Treated With Non–Vitamin K Antagonist Oral Anticoagulants

  2015cited by this paper
• Intravenous thrombolysis in stroke patients receiving rivaroxaban

  2014cited by this paper
• The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

  2014cited by this paper
• European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

  2014cited by this paper
• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

  2013cited by this paper
• Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban

  2013cited by this paper
• IV thrombolysis and renal function

  2013cited by this paper
• Vitamin K Antagonists–Associated Cerebral Hemorrhages: What Are Their Characteristics?

  2013cited by this paper
• Factors influencing the decline in stroke mortality: A statement for healthcare professionals from the American Heart Association/American Stroke Association

  2013cited by this paper
• Measurement of the new anticoagulants.

  2012cited by this paper
• Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

  2011cited by this paper
• Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/american Stroke Association".

  2011cited by this paper
• Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

  2011cited by this paper
• IV thrombolysis and statins

  2011cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• What causes intracerebral hemorrhage during warfarin therapy?

  2000cited by this paper
• Improved Reliability of the NIH Stroke Scale Using Video Training

  1994cited by this paper
• O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper

• Urine-based point-of-care detection of direct oral anticoagulant activity in acute stroke—accuracy at anti-Xa thresholds relevant for intravenous thrombolysis

  2025cites this paper
• Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants

  2025cites this paper
• Ischemic Stroke in Patients Under Oral Anticoagulation: The Achilles Heel of Atrial Fibrillation Management

  2025cites this paper
• Dielectric blood coagulometry to evaluate coagulation activity in patients prescribed factor Xa inhibitors undergoing elective surgery: A prospective observational study.

  2025cites this paper
• Direct oral anticoagulants in trauma patients

  2024cites this paper
• DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study

  2023cites this paper
• Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study

  2023cites this paper
• Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy

  2023cites this paper
• Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation

  2023cites this paper
• Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial

  2023cites this paper
• Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.

  2022cites this paper
• Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants

  2022cites this paper
• Role of DOAC plasma concentration on perioperative blood loss and transfusion requirements in patients with hip fractures

  2022cites this paper
• Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta-analysis

  2022cites this paper
• Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study

  2022cites this paper
• Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events

  2022cites this paper
• Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation

  2022cites this paper
• Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity

  2022cites this paper
• Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants

  2021cites this paper
• Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants

  2021cites this paper
• Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data

  2021cites this paper
• Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants: To Treat or How to Treat.

  2021cites this paper
• Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants

  2021cites this paper
• Coagulation Assay and Stroke Severity upon Admission of Patients with Cardioembolic Cerebral Infarction during Direct Oral Anticoagulant Use.

  2021cites this paper
• Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

  2021cites this paper
• Ischaemic stroke in anticoagulated patients with atrial fibrillation

  2021cites this paper
• Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs)

  2021cites this paper
• Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography

  2021cites this paper
• Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option?

  2021cites this paper
• Idarucizumab before reperfusion therapy in stroke patients on dabigatran

  2020cites this paper
• Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

  2020cites this paper
• A prospective observational study of the rapid detection of clinically‐relevant plasma direct oral anticoagulant levels following acute traumatic injury

  2020cites this paper
• Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation

  2020cites this paper
• Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature

  2020cites this paper
• Antithrombotic therapy in patients with recent stroke and atrial fibrillation.

  2020cites this paper
• Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke

  2020cites this paper
• Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?

  2020cites this paper
• Patients on NOACs in the Emergency Room

  2019cites this paper
• Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.

  2019cites this paper
• Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants – A systematic review

  2019cites this paper
• MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists

  2019cites this paper
• Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

  2019cites this paper
• Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers

  2019cites this paper
• Atrial fibrillation and stroke: a practical guide

  2019cites this paper
• Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications

  2018cites this paper
• Management of patients with stroke treated with direct oral anticoagulants

  2018cites this paper
• When less is more (brain)—comment on “Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage”

  2018cites this paper
• Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.

  2018cites this paper
• Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

  2018cites this paper
• Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

  year unknowncites this paper